02877.HK
China Shineway Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 8.26
+0.85%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.0B | 3.1B | 3.8B | 4.5B | 4.0B |
| Cost of Revenue | 1.7B | 869.2M | 946.3M | 1.1B | 1.0B |
| Gross Profit | 4.3B | 2.3B | 2.8B | 3.4B | 2.9B |
| Operating Expenses | |||||
| R&D Expense | 224.9M | 103.1M | 100.5M | 110.5M | 117.5M |
| SG&A Expense | 2.8B | 1.4B | 1.9B | 2.3B | 2.1B |
| General & Admin Expense | 425.8M | 279.7M | 291.3M | 326.5M | 279.8M |
| Selling & Marketing Expense | 1.9B | 1.2B | 1.6B | 2.0B | 1.8B |
| Other Expenses | 35.7M | 35.7M | — | — | (8.8M) |
| Total Operating Expenses | 3.0B | 1.6B | 2.0B | 2.4B | 2.2B |
| Cost and Expenses | 4.7B | 2.5B | 2.9B | 3.5B | 3.2B |
| Operating Income (EBIT) | 1.3B | 682.1M | 842.6M | 975.5M | 713.6M |
| Non-Operating | |||||
| Interest Income | 483.7M | 216.4M | 176.7M | 95.2M | 92.4M |
| Interest Expense | 2.2M | 5.7M | 6.1M | 2.7M | 630.0K |
| Net Interest Income | 481.5M | 210.7M | 170.6M | 92.5M | 91.8M |
| Other Non-Op Income/Expense | 821.0M | 587.2M | 303.1M | 270.2M | 203.4M |
| Non-Operating Income (excl Interest) | — | — | 6.6M | (267.5M) | (204.1M) |
| EBT (Pre-Tax Income) | 2.1B | 1.3B | 1.1B | 1.2B | 917.0M |
| Income Tax Expense | 487.2M | 319.3M | 305.7M | 270.7M | 194.3M |
| Bottom Line | |||||
| Net Income | 1.6B | 949.9M | 840.1M | 969.5M | 722.8M |
| Earnings from Cont. Ops | 1.6B | 949.9M | 840.1M | 969.5M | 722.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.6B | 949.9M | 840.1M | 969.5M | 722.8M |
| Per Share | |||||
| Basic EPS | HK$2.14 | HK$1.26 | HK$1.11 | HK$1.28 | HK$0.96 |
| Diluted EPS | HK$2.14 | HK$1.26 | HK$1.11 | HK$1.28 | HK$0.96 |
| Revenue Per Share | HK$7.93 | HK$4.15 | HK$5.00 | HK$5.98 | HK$5.23 |
| Shares | |||||
| Basic Shares Outstanding | 755.4M | 755.4M | 755.4M | 755.4M | 755.4M |
| Diluted Shares Outstanding | 755.4M | 755.4M | 755.4M | 755.4M | 755.4M |
| Profitability Metrics | |||||
| EBITDA | 1.6B | 739.5M | 1.0B | 1.4B | 1.1B |
| D&A | 304.5M | 57.5M | 165.9M | 177.1M | 185.9M |
| EBIT | 1.3B | 682.1M | 836.0M | 1.2B | 917.7M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026